BioCentury | Aug 25, 2016
Distillery Therapeutics

Therapeutics: WAS protein family member 3 (WASF3); NCK associated protein 1 (NCKAP1); cytoplasmic FMR1 interacting protein 1 (CYFIP1)

...INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest that inhibiting the WASF3-NCKAP1- CYFIP1...
...two human breast cancer cell lines, shRNA targeting NCKAP1 or a stapled peptide inhibiting the NCKAP1-CYFIP1...
...with unmodified expression of NCKAP1 and WASF3. Next steps could include testing inhibition of the WASF3-NCKAP1-CYFIP1...
BioCentury | Jun 25, 2009
Distillery Therapeutics

Indication: Cancer

...Epithelial cancer Cytoplasmic FMR1-interacting protein 1 (CYFIP1) Patient samples and studies in mice suggest that CYFIP1...
...that enhancing its activity could help treat epithelial cancers. In various human epithelial cancers, low CYFIP1...
...tumor invasiveness reduced Cyfip1 expression. Next steps could include studies to determine how disruption of CYFIP1...
Items per page:
1 - 2 of 2